FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of general formula (1) and pharmaceutically acceptable salts thereof, which exhibit inhibitory activity on phospholipase A2 enzyme and therefore have prostaglandin and/or leucotriene production suppressing action. In formula 
X is a halogen atom, cyano group, C1-C3 alkyl group, which can be substituted with halogen atoms, C1-C3 alkoxy group or hydroxy group, C2-C4 alkenyl group, C1-C3 alkoxy group or hydroxy group; Y is a hydrogen atom or C1-C3 alkyl group; Z is C1-C3 alkyl group; G is selected from formulae 
and 
, where in formulae (G2) and (G5) R4 is a hydrogen atom or C1-C6 alkyl group which can be substituted with halogen atoms; D is -NR10C(O)-, -C(O)NR10-, -S(O)2NR10- or -N(R11)-; R10 is a hydrogen atom; R11 is a hydrogen atom or C1-C3 alkyl group; A is a single bond, C1-C6 alkylene, which can be substituted with a phenyl group, or C2-C4 alkenylene; Q is a phenyl group or a 5-6-member aromatic heterocyclic group containing 1-3 heteroatoms selected from N, O, S, optionally substituted with a benzene ring; R5, R6 and R7 all or independently denote a hydrogen atom, a halogen atom, C1-C6 alkyl group which can be substituted with halogen atoms, C1-C6 alkoxy group which can be substituted with halogen atoms, phenyloxy group, phenyl group or a 5-6-member aromatic heterocyclic group containing 1-3 heteroatoms selected from N, O, where said phenyl group and 5-6-member aromatic heterocyclic group can be substituted with a C1-C3 alkyl group which can be substituted with halogen atoms or a C1-C3 alkoxy group. The invention also relates to specific compounds, a medicinal agent, a pharmaceutical composition, a phospholipase A2 enzyme activity inhibitor and a treatment method.
EFFECT: improved method.
21 cl, 56 tbl, 561 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SULFONAMIDE COMPOUND | 2006 |
|
RU2376300C1 |
| NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS | 2009 |
|
RU2477281C2 |
| STABLE EMULSION COMPOSITION | 2006 |
|
RU2428204C2 |
| THERAPEUTIC DRUG OR PREVENTIVE THERAPEUTIC AGENT FOR DIABETIC NEPHROPATHY | 2017 |
|
RU2735538C1 |
| DERIVATIVE OF THIOBENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | 1999 |
|
RU2237663C2 |
| ANTITUMOR EFFECT STRENGTHENING AGENT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | 2018 |
|
RU2799006C2 |
| 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE | 2020 |
|
RU2796605C2 |
| ENANTIOSELECTIVE METHOD OF PRODUCING SULFOXIDE DERIVATIVES | 2005 |
|
RU2380357C2 |
| DERIVATIVES OF PYRAZOLE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND INTERMEDIATE COMPOUNDS OF SYNTHESIS | 1993 |
|
RU2119917C1 |
| PHARMACEUTICAL COMPOSITION, METHOD FOR ITS PREPARING AND USING | 2006 |
|
RU2303597C1 |
